AAB 003
Alternative Names: AAB-003; PF-05236812; PF-5236812Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Elan Corporation; Wyeth
- Developer JANSSEN Alzheimer Immunotherapy; Pfizer
- Class Antibodies; Antidementias; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 06 Nov 2014 Discontinued - Phase-I for Alzheimer's disease in USA and South Korea (IV)
- 31 Aug 2014 Pfizer & JANSSEN Alzheimer Immunotherapy complete a phase I trial for Alzheimer's disease in USA & South Korea (NCT01369225)
- 12 Dec 2013 Pfizer & JANSSEN Alzheimer Immunotherapy suspend enrolment in a phase I extension trial for Alzheimer's disease in USA and South Korea (NCT01369225)